AbbVie, Inc. (ABBV)
256.35
+0.87
(+0.34%)
USD |
NYSE |
Aug 31, 16:00
257.00
+0.65
(+0.25%)
After-Hours: 18:40
AbbVie Cash from Operations (TTM) : 19.51B for June 30, 2026
Cash from Operations (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 19.51B |
| March 31, 2026 | 21.22B |
| December 31, 2025 | 19.03B |
| September 30, 2025 | 20.86B |
| June 30, 2025 | 19.28B |
| March 31, 2025 | 16.40B |
| December 31, 2024 | 18.81B |
| September 30, 2024 | 16.47B |
| June 30, 2024 | 18.60B |
| March 31, 2024 | 22.65B |
| December 31, 2023 | 22.80B |
| September 30, 2023 | 25.51B |
| June 30, 2023 | 25.54B |
| March 31, 2023 | 24.23B |
| December 31, 2022 | 24.94B |
| September 30, 2022 | 22.59B |
| June 30, 2022 | 22.92B |
| March 31, 2022 | 22.81B |
| December 31, 2021 | 22.78B |
| September 30, 2021 | 22.56B |
| June 30, 2021 | 20.45B |
| March 31, 2021 | 18.65B |
| December 31, 2020 | 17.59B |
| September 30, 2020 | 16.01B |
| June 30, 2020 | 14.90B |
| Date | Value |
|---|---|
| March 31, 2020 | 14.12B |
| December 31, 2019 | 13.32B |
| September 30, 2019 | 13.44B |
| June 30, 2019 | 13.24B |
| March 31, 2019 | 13.80B |
| December 31, 2018 | 13.43B |
| September 30, 2018 | 12.62B |
| June 30, 2018 | 11.37B |
| March 31, 2018 | 10.50B |
| December 31, 2017 | 9.96B |
| September 30, 2017 | 8.917B |
| June 30, 2017 | 7.10B |
| March 31, 2017 | 7.015B |
| December 31, 2016 | 7.041B |
| September 30, 2016 | 7.463B |
| June 30, 2016 | 8.164B |
| March 31, 2016 | 8.078B |
| December 31, 2015 | 7.535B |
| September 30, 2015 | 4.994B |
| June 30, 2015 | 4.625B |
| March 31, 2015 | 4.51B |
| December 31, 2014 | 3.549B |
| September 30, 2014 | 5.372B |
| June 30, 2014 | 5.384B |
| March 31, 2014 | 5.704B |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (TTM) Benchmarks
| Biogen, Inc. | 2.879B |
| Gilead Sciences, Inc. | 13.55B |
| Regeneron Pharmaceuticals, Inc. | 4.681B |
| Amgen, Inc. | 12.48B |
| REGENXBIO, Inc. | -246.67M |